Loading...
XHKG
1011
Market cap7mUSD
Feb 13, Last price  
0.23HKD
Name

China NT Pharma Group Company Ltd

Chart & performance

D1W1MN
XHKG:1011 chart
P/E
—
P/S
2.16
EPS
—
Vol. 1Y
—
Shs. 5Y
-20.04%
Rev. 5Y
-35.81%
Div Yld LY
—
Div Yld TTM
—
Revenues
24m
-36.36%
2,667,978,0002,758,142,000739,132,000754,115,000864,621,000847,726,000915,119,000604,846,000571,521,000365,969,000221,731,000226,699,000207,092,0007,366,00037,960,00024,158,000
Net income
-26m
L-51.19%
128,610,000234,377,000-1,109,316,000-673,458,0002,087,00087,694,000116,181,000165,195,000-957,666,000-593,202,000-357,599,000-149,538,000-66,405,000-143,590,000-53,357,000-26,041,000
CFO
-25m
L+170.80%
-383,235,000-206,326,000-6,842,000-38,480,00072,723,000-97,398,00020,693,000147,561,000-124,203,00047,765,00026,204,000-134,775,00036,210,00050,476,000-9,066,000-24,550,717
Dividend
Jul 10, 20180.035 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.

Key people

Tit Ng
Executive Chairman of the Board, Chief Executive Officer
Jing Fang
Chief Financial Officer · since 2019
Baoming Ge
General Manager of Corporate Development and Product Research and Development Centre
Yu Chin
Executive Director · since 2015
Fei Wang
Chief Financial Officer, Executive Director · since 2019
Weizhong Wu
Executive Director · since 2015
Biao Gui
Director of Sales, Director of Marketing · since 2014
Siu Kuen Lai
Company Secretary · since 2018
Wei Qian
Non-Executive Director · since 2010
Non-Executive Independent Director · since 2020
Independent Non-Executive Director · since 2010
Independent Non-Executive Director · since 2017
Independent Non-Executive Director · since 2019
IPO date
Apr 20, 2011
Employees
124
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT